Berubicin showed clinically relevant outcomes comparable to Lomustine across multiple endpoints, but not a statistically significant difference in overall survival, the primary endpoint.

The clinical trial pitted Berubicin, an anthracycline known for its ability to cross the blood-brain barrier, against Lomustine, a standard care treatment for recurrent or progressive Glioblastoma ...

Berubicin showed clinically relevant outcomes comparable to Lomustine across multiple endpoints, but not a statistically significant difference in overall survival, the primary endpoint.